NCT06589609 - Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2029

Conditions

Oropharyngeal Squamous Cell Carcinoma (SCC)

Interventions

BIOLOGICAL

FluBHPVE6E7

Intratumoral administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule.

Trial Locations (1)

1090

RECRUITING

Medical University Vienna, Vienna